Merck & Co., Inc. (MRK) financials: revenue, earnings and cash flow
Fiscal 2016–2025 + TTM · from SEC filings · data as of November 13, 2026
Summary
Merck & Co.’s revenue went from $39.8B in fiscal 2016 to $65.0B in fiscal 2025, growth of about 5.6% a year.
Net income in fiscal 2025 was $18.3B, a net margin of 28.1%; the highest of the period.
Over the twelve months to September 30, 2026, revenue was $67.4B and net income $2.5B.
Free cash flow was $12.4B in fiscal 2025 and positive in 10 of the 10 years shown.
The diluted share count fell 10% over the period (buybacks).
Revenue, profit and cash flow by year
Income statement
| Fiscal year | TTM | 2025 | 2024 | 2023 | 2022 | 2021 | 2020 | 2019 | 2018 | 2017 | 2016 |
|---|---|---|---|---|---|---|---|---|---|---|---|
| Revenue | $67.4B | $65.0B | $64.2B | $60.1B | $59.3B | $48.7B | $41.5B | $39.1B | $42.3B | $40.1B | $39.8B |
| Gross profit | $48.3B | $48.6B | $49.0B | $44.0B | $41.9B | $35.1B | $27.9B | $27.1B | $28.8B | $27.2B | $25.8B |
| Operating income | $6.7B | $22.4B | $21.2B | $3.0B | $17.4B | $14.7B | $6.7B | $8.1B | $9.5B | $7.3B | $5.4B |
| Net income | $2.5B | $18.3B | $17.1B | $365M | $14.5B | $13.0B | $7.1B | $9.8B | $6.2B | $2.4B | $3.9B |
| EPS (diluted) | $0.98 | $7.28 | $6.74 | $0.14 | $5.71 | $5.14 | $2.78 | $3.81 | $2.32 | $0.87 | $1.41 |
| R&D | $30.8B | $15.8B | $17.9B | $30.5B | $13.5B | $12.2B | $13.4B | $9.7B | $9.8B | $10.3B | $10.3B |
| Revenue growth | — | +1.3% | +6.7% | +1.4% | +21.7% | +17.3% | +6.1% | −7.5% | +5.4% | +0.8% | +0.8% |
Cash flow
| Fiscal year | TTM | 2025 | 2024 | 2023 | 2022 | 2021 | 2020 | 2019 | 2018 | 2017 | 2016 |
|---|---|---|---|---|---|---|---|---|---|---|---|
| Operating cash flow | $18.7B | $16.5B | $21.5B | $13.0B | $19.1B | $13.1B | $10.3B | $13.4B | $10.9B | $6.5B | $10.4B |
| Capital spending | -$4.0B | -$4.1B | -$3.4B | -$3.9B | -$4.4B | -$4.4B | -$4.4B | -$3.4B | -$2.6B | -$1.9B | -$1.6B |
| Free cash flow | $14.7B | $12.4B | $18.1B | $9.1B | $14.7B | $8.7B | $5.8B | $10.1B | $8.3B | $4.6B | $8.8B |
| Dividends paid | $8.4B | $8.2B | $7.8B | $7.4B | $7.0B | $6.6B | $6.2B | $5.7B | $5.2B | $5.2B | $5.1B |
| Buybacks | $3.5B | $5.1B | $1.3B | $1.3B | $0 | $840M | $1.3B | $4.8B | $9.1B | $4.0B | $3.4B |
| Stock-based pay | $1.1B | $820M | $761M | $645M | $541M | $479M | $441M | $388M | $348M | $312M | $300M |
Balance sheet
| Fiscal year | TTM | 2025 | 2024 | 2023 | 2022 | 2021 | 2020 | 2019 | 2018 | 2017 | 2016 |
|---|---|---|---|---|---|---|---|---|---|---|---|
| Cash | — | $14.6B | $13.7B | $7.1B | $13.2B | $8.1B | $8.1B | $10.4B | $8.9B | $8.5B | $14.3B |
| Debt | — | $50.5B | $38.3B | $36.3B | $32.0B | $34.6B | $33.4B | $27.3B | $25.1B | $24.4B | $24.6B |
| Equity | — | $52.6B | $46.3B | $37.6B | $46.0B | $38.2B | $25.3B | $25.9B | $26.7B | $34.3B | $40.1B |
| Total assets | — | $136.9B | $117.1B | $106.7B | $109.2B | $105.7B | $91.6B | $84.4B | $82.6B | $87.9B | $95.4B |
| Shares (diluted) | 2.48B | 2.51B | 2.54B | 2.55B | 2.54B | 2.54B | 2.54B | 2.58B | 2.68B | 2.75B | 2.79B |
Margins and returns
| Fiscal year | TTM | 2025 | 2024 | 2023 | 2022 | 2021 | 2020 | 2019 | 2018 | 2017 | 2016 |
|---|---|---|---|---|---|---|---|---|---|---|---|
| Gross margin | 71.8% | 74.8% | 76.3% | 73.2% | 70.6% | 72.0% | 67.2% | 69.3% | 68.1% | 67.8% | 64.8% |
| Operating margin | 10.0% | 34.5% | 33.1% | 5.1% | 29.4% | 30.1% | 16.1% | 20.6% | 22.4% | 18.1% | 13.4% |
| Net margin | 3.6% | 28.1% | 26.7% | 0.6% | 24.5% | 26.8% | 17.0% | 25.2% | 14.7% | 6.0% | 9.8% |
| FCF margin | 21.9% | 19.0% | 28.2% | 15.2% | 24.8% | 17.8% | 14.0% | 25.7% | 19.6% | 11.4% | 22.0% |
| ROIC | — | 18.9% | 21.6% | 3.2% | 19.7% | 18.0% | 8.8% | 11.8% | 13.0% | 9.8% | 7.0% |
| ROE | — | 34.7% | 37.0% | 1.0% | 31.6% | 34.2% | 27.9% | 38.0% | 23.3% | 7.0% | 9.8% |
Frequently asked questions
What is Merck & Co.’s annual revenue?
$65.0B in fiscal 2025 and $67.4B over the twelve months to September 30, 2026.
How much profit does Merck & Co. make?
Net income was $18.3B in fiscal 2025 (net margin 28.1%).
Is Merck & Co.’s revenue growing?
Yes: revenue rose 1.3% in fiscal 2025 compared with the year before.
From the company’s 10-K and 10-Q filings with the SEC; per-share figures adjusted for stock splits. Rebuilt daily. Not investment advice.